MedTrace Logo

Ramelteon Prevention of Delirium - RCT

NCT02564939 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2018-08-01

No results posted yet for this study

Summary

Delirium is a common morbid condition in hospitalized adults. Treatment of delirium has been unsatisfactory and prevention is the preferred goal. Based on limited experimental research, ramelteon appears to have promise for prevention. This study will evaluate ramelteon in prevention of delirium in a hospitalized adult population age 65+ in a double-blinded RCT.

Conditions

  • Delirium

Interventions

DRUG

ramelteon

double-blind RCT

DRUG

Placebo

double-blind RCT

Sponsors & Collaborators

  • Hartford Hospital

    lead OTHER

Principal Investigators

  • Robert S Dicks, MD · Hartford Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-23
Primary Completion
2018-12-31
Completion
2019-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02564939 on ClinicalTrials.gov